Novo Nordisk unveiled trial results for CagriSema, its prospective blockbuster treatment for obesity and diabetes, which demonstrated a 15.7% weight loss in type 2 diabetes patients over 68 weeks. Despite the promising data, the company’s shares declined, reflecting lower-than-anticipated weight loss figures that failed to meet market expectations.
About the Author
